WEDNESDAY, June 25, 2025 (HealthDay News) -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large cell ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates (ADCs)—in a Lunsumio-Polivy regimen in large B-cell lymphoma (LBCL ...

CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 WaveLINE-003 trial of patients with relapsed/refractory diffuse B-cell lymphoma ...

“We believe that these data support the use of Glofit-GemOx as a preferred second-line treatment option, which offers patients with nontransplant eligible, diffuse large B-cell lymphoma access ...

It's possible that implant-associated lymphoma is yet another cancer that can arise because of these genetic mutations." ...

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma Provided by PR Newswire Jun 13, 2025, 8:00:00 AM ...

Breast cancer patients with BRCA mutations and textured implants found to have increased risk of rare lymphoma by American Society of Hematology ...

7078Background: Anaplastic lymphoma kinase positive anaplastic large cell lymphoma (ALK+ ALCL) is a rare subtype of peripheral T-cell lymphoma, characterized by CD 30+ large pleomorphic lymphoid cells ...

ALK-positive anaplastic large cell lymphoma: Statistics and survival trends. Second primary malignancy in patients with diffuse large B-cell lymphoma (DLBCL) receiving chimeric antigen receptor T-cell ...

Roche is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.